Cramer's Morning Take: Eli Lilly & Novo Nordisk 1/24/25
Squawk on the Street
00:00
Eli Lilly's Recovery: Prescription Growth Insights
This chapter highlights Eli Lilly's recent increase in weekly prescription growth following a lackluster fourth quarter. It also compares Lilly's prospects with Novo Nordisk's drug tolerability while discussing ongoing developments like a new amylin molecule.
Transcript
Play full episode
